Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025884090> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2025884090 abstract "Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, ILRecent evidences point to ERBB3 as a critical activator of the PI3K/Akt signaling axis and suggest that its trans-phosphorylation is linked to the occurrence of drug resistance in several cancers. Because of the absence of a functional tyrosine kinase, the best approach to target this receptor is through the development of selective monoclonal antibodies. For this purpose, our group has recently generated a set of mouse monoclonals with low nM affinity for human ERBB3. We have started to assess the effect of these antibodies in lung cancer using two systems: a) PC9 cells, known to be highly sensitive to gefitinib (IC50 0,03 uM), for the DelE746A750 in exon 19 of EGFR and its gefitinib-resistant counterpart PC9-ZD (Koizumi et al, 2005 Int J. Cancer 116, 36); b) primary lung adenocarcinoma cells isolated in our laboratory from Malignant Pleural Effusions (MPEs) and capable of efficient tumor propagation in vivo (Mancini et al, 2011, PlosONE 6: e21320). In PC9 cells anti-ERBB3 mabs, A3 and A4, strongly inhibit ligand-induced pHER3 and pAKT and induce receptor downmodulation. Furthermore, A3 and A4 potentiate the antiproliferative effect of gefitinib in a clonogenic assay, induce G0/G1 arrest, and increase the percentage of cells that undergo apoptosis. In the human primary MPE-derived lung adenocarcinoma culture PEd10, we observed that the expression of ERBB3 and its ligand are upregulated when cells are grown in spheroid vs adherent conditions. In this system, A3 and A4 antibodies significantly downmodulate spheroid propagation. Studies are ongoing to provide further insights as to the mechanism of action of anti-ERBB3 antibodies and to confirm efficacy in in vivo tumor models. Our results suggest that in a subset of lung adenocarcinomas which express high levels of ERBB3, this receptor contributes to cell growth and propagation and that targeting ERBB3 with antibodies capable of inducing receptor downmodulation can be considered a promising therapeutic approach.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2846. doi:1538-7445.AM2012-2846" @default.
- W2025884090 created "2016-06-24" @default.
- W2025884090 creator A5015058883 @default.
- W2025884090 creator A5020699728 @default.
- W2025884090 creator A5024942799 @default.
- W2025884090 creator A5025909416 @default.
- W2025884090 creator A5052593572 @default.
- W2025884090 creator A5059750492 @default.
- W2025884090 creator A5070689739 @default.
- W2025884090 date "2012-04-15" @default.
- W2025884090 modified "2023-09-25" @default.
- W2025884090 title "Abstract 2846: Exploring ERBB3 as novel drug target in lung cancer" @default.
- W2025884090 doi "https://doi.org/10.1158/1538-7445.am2012-2846" @default.
- W2025884090 hasPublicationYear "2012" @default.
- W2025884090 type Work @default.
- W2025884090 sameAs 2025884090 @default.
- W2025884090 citedByCount "0" @default.
- W2025884090 crossrefType "proceedings-article" @default.
- W2025884090 hasAuthorship W2025884090A5015058883 @default.
- W2025884090 hasAuthorship W2025884090A5020699728 @default.
- W2025884090 hasAuthorship W2025884090A5024942799 @default.
- W2025884090 hasAuthorship W2025884090A5025909416 @default.
- W2025884090 hasAuthorship W2025884090A5052593572 @default.
- W2025884090 hasAuthorship W2025884090A5059750492 @default.
- W2025884090 hasAuthorship W2025884090A5070689739 @default.
- W2025884090 hasConcept C101544691 @default.
- W2025884090 hasConcept C115456853 @default.
- W2025884090 hasConcept C121608353 @default.
- W2025884090 hasConcept C126322002 @default.
- W2025884090 hasConcept C143998085 @default.
- W2025884090 hasConcept C170493617 @default.
- W2025884090 hasConcept C190283241 @default.
- W2025884090 hasConcept C2776256026 @default.
- W2025884090 hasConcept C2779438470 @default.
- W2025884090 hasConcept C2780580887 @default.
- W2025884090 hasConcept C2781182431 @default.
- W2025884090 hasConcept C502942594 @default.
- W2025884090 hasConcept C55493867 @default.
- W2025884090 hasConcept C71924100 @default.
- W2025884090 hasConcept C75217442 @default.
- W2025884090 hasConcept C86803240 @default.
- W2025884090 hasConceptScore W2025884090C101544691 @default.
- W2025884090 hasConceptScore W2025884090C115456853 @default.
- W2025884090 hasConceptScore W2025884090C121608353 @default.
- W2025884090 hasConceptScore W2025884090C126322002 @default.
- W2025884090 hasConceptScore W2025884090C143998085 @default.
- W2025884090 hasConceptScore W2025884090C170493617 @default.
- W2025884090 hasConceptScore W2025884090C190283241 @default.
- W2025884090 hasConceptScore W2025884090C2776256026 @default.
- W2025884090 hasConceptScore W2025884090C2779438470 @default.
- W2025884090 hasConceptScore W2025884090C2780580887 @default.
- W2025884090 hasConceptScore W2025884090C2781182431 @default.
- W2025884090 hasConceptScore W2025884090C502942594 @default.
- W2025884090 hasConceptScore W2025884090C55493867 @default.
- W2025884090 hasConceptScore W2025884090C71924100 @default.
- W2025884090 hasConceptScore W2025884090C75217442 @default.
- W2025884090 hasConceptScore W2025884090C86803240 @default.
- W2025884090 hasLocation W20258840901 @default.
- W2025884090 hasOpenAccess W2025884090 @default.
- W2025884090 hasPrimaryLocation W20258840901 @default.
- W2025884090 hasRelatedWork W1965697171 @default.
- W2025884090 hasRelatedWork W1966067305 @default.
- W2025884090 hasRelatedWork W1969091416 @default.
- W2025884090 hasRelatedWork W1975240042 @default.
- W2025884090 hasRelatedWork W1980984439 @default.
- W2025884090 hasRelatedWork W2020506545 @default.
- W2025884090 hasRelatedWork W2032693508 @default.
- W2025884090 hasRelatedWork W2065759895 @default.
- W2025884090 hasRelatedWork W2083620422 @default.
- W2025884090 hasRelatedWork W2094797748 @default.
- W2025884090 hasRelatedWork W2258459776 @default.
- W2025884090 hasRelatedWork W2316509354 @default.
- W2025884090 hasRelatedWork W2319566158 @default.
- W2025884090 hasRelatedWork W2320340098 @default.
- W2025884090 hasRelatedWork W2324910661 @default.
- W2025884090 hasRelatedWork W2328619089 @default.
- W2025884090 hasRelatedWork W2329016057 @default.
- W2025884090 hasRelatedWork W2562564824 @default.
- W2025884090 hasRelatedWork W2953762343 @default.
- W2025884090 hasRelatedWork W2955178987 @default.
- W2025884090 isParatext "false" @default.
- W2025884090 isRetracted "false" @default.
- W2025884090 magId "2025884090" @default.
- W2025884090 workType "article" @default.